Skip to main content
Premium Trial:

Request an Annual Quote

British Columbia Cancer Agency Agrees to Fund Genomic Health's Oncotype DX

NEW YORK (GenomeWeb) ─ The British Columbia Cancer Agency has agreed to reimburse for Genomic Health's Oncotype DX breast cancer recurrence test.

The multi-gene expression diagnostic is available in four other Canadian provinces in addition to British Columbia, including Ontario, Quebec, Saskatchewan, and Newfoundland.

"Understanding a patient's individual tumor biology gives us greater confidence in recommending a personalized treatment that is better suited for that patient," Stephen Chia, oncologist and clinical investigator with the BC Cancer Agency, said in a statement.

Chia conducted a study published last year in the European Journal of Cancer showing that when physicians used Oncotype DX to guide treatment strategies for women with early stage, invasive, hormone receptor-positive breast cancer, they changed their therapy recommendations 30 percent of the time. The same study also showed that the use of Oncotype DX in this subset of women was cost effective in British Columbia's publicly funded healthcare system.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.